Substituted benzimidazole derivative as a modulator of TNF activity
2-(5-{1-[2-(Difluoromethoxy)-6-fluorobenzyl]-2-methyl-1H-benzimidazol-6-yl}pyrimidin-2-yl)propan-2-ol, or a pharmaceutically acceptable salt thereof, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
1. 2-(5-{1-[2-(Difluoromethoxy)-6-fluorobenzyl]-2-methyl-1H-benzimidazol-6-yl}pyrimidin-2-yl)propan-2-ol, or a pharmaceutically acceptable salt thereof.
2. A pharmaceutical composition comprising 2-(5-{1-[2-(difluoromethoxy)-6-fluorobenzyl]-2-methyl-1H-benzimidazol-6-yl}pyrimidin-2-yl)propan-2-ol, or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable carrier.
3. The pharmaceutical composition as claimed in claim 2 further comprising an additional pharmaceutically active ingredient.
4. A method for the treatment of disorders for which the administration of a modulator of TNFα function is indicated which comprises administering to a patient in need of such treatment an effective amount of 2-(5-{1-[2-(difluoromethoxy)-6-fluorobenzyl]-2-methyl- 1H-benzimidazol-6-yl}pyrimidin-2-yl)-propan-2-ol, or a pharmaceutically acceptable salt thereof.
5. A method for the treatment of myocardial infarction, leukemia, melanoma, sarcoma, breast cancer, ovarian cancer, pancreatic cancer, renal cell carcinoma, prostate cancer, rheumatoid arthritis, Crohn's disease, multiple sclerosis and inflammatory bowel disease, which comprises administering to a patient in need of such treatment an effective amount of 2-(5-{1-[2-(difluoromethoxy)-6-fluorobenzyl]-2-methyl-1H-benzimidazol-6-yl}pyrimidin-2-yl)propan-2-ol, or a pharmaceutically acceptable salt thereof.